Basophils and Autoreactive IgE in the Pathogenesis of Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a heterogeneous disease that can affect multiple organs. A hallmark of this disease, as is the case for other autoimmune diseases, is the presence of large numbers of autoantibodies. As such, SLE is considered to be a B-cell disease perpetuated by the expansion...

Full description

Saved in:
Bibliographic Details
Published inCurrent allergy and asthma reports Vol. 11; no. 5; pp. 378 - 387
Main Authors Charles, Nicolas, Rivera, Juan
Format Journal Article
LanguageEnglish
Published New York Current Science Inc 01.10.2011
Springer Nature B.V
Subjects
Allergology
Animals
Antibody Formation
Autoantibodies - immunology
Basophils - immunology
Basophils - pathology
Disease Models, Animal
Humans
Immunoglobulin E - immunology
Lupus Erythematosus, Systemic - immunology
Lupus Erythematosus, Systemic - pathology
Lymphocytes - immunology
Lymphocytes - pathology
Medicine
Medicine & Public Health
Mice
Lupus
Interleukin-4
Systemic lupus erythematosus
Basophils
IgE
Autoantibody
IL-4
Online AccessGet full text
ISSN1529-7322
1534-6315
1534-6315
DOI10.1007/s11882-011-0216-5

Cover

More Information
Summary:Systemic lupus erythematosus (SLE) is a heterogeneous disease that can affect multiple organs. A hallmark of this disease, as is the case for other autoimmune diseases, is the presence of large numbers of autoantibodies. As such, SLE is considered to be a B-cell disease perpetuated by the expansion of autoreactive T and B cells. The T cells involved have long been considered to be T-helper type 1 (Th1) and Th17 cells, as these potent proinflammatory cells can be found in the tissues of SLE patients. Recent advances point to a role for the Th2 environment in contributing to SLE through promotion of autoantibody production. Here we describe the recent work focusing on autoreactive IgE and the activation of basophils as promoting the production of autoantibodies in SLE. The findings, both in a murine model of SLE and in humans with SLE, support the concept that the activation of the basophil by autoreactive IgE-containing immune complexes serves to amplify the production of autoantibodies and contributes to the pathogenesis of disease. We propose that therapeutic targeting of this amplification loop by reducing the levels of circulating autoreactive IgE may have benefit in SLE.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1529-7322
1534-6315
1534-6315
DOI:10.1007/s11882-011-0216-5